Chris D Greenman

Summary

Affiliation: Wellcome Trust Genome Campus
Country: UK

Publications

  1. pmc PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data
    Chris D Greenman
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK
    Biostatistics 11:164-75. 2010
  2. pmc Signatures of mutation and selection in the cancer genome
    Graham R Bignell
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 463:893-8. 2010
  3. pmc Statistical analysis of pathogenicity of somatic mutations in cancer
    Chris Greenman
    Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    Genetics 173:2187-98. 2006
  4. pmc Massive genomic rearrangement acquired in a single catastrophic event during cancer development
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
    Cell 144:27-40. 2011
  5. pmc GLO1-A novel amplified gene in human cancer
    Thomas Santarius
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK
    Genes Chromosomes Cancer 49:711-25. 2010
  6. pmc A comprehensive catalogue of somatic mutations from a human cancer genome
    Erin D Pleasance
    Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 463:191-6. 2010
  7. pmc Complex landscapes of somatic rearrangement in human breast cancer genomes
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 462:1005-10. 2009
  8. pmc The relative timing of mutations in a breast cancer genome
    Scott Newman
    Hutchison MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    PLoS ONE 8:e64991. 2013
  9. pmc Estimation of rearrangement phylogeny for cancer genomes
    Chris D Greenman
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom
    Genome Res 22:346-61. 2012
  10. pmc Systematic identification of genomic markers of drug sensitivity in cancer cells
    Mathew J Garnett
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 483:570-5. 2012

Collaborators

Detail Information

Publications10

  1. pmc PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data
    Chris D Greenman
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK
    Biostatistics 11:164-75. 2010
    ..These methods are exemplified with affymetrix genome-wide SNP6.0 data from 755 cancer cell lines, enabling inference upon a number of features of biological interest. These data and the coded algorithm are freely available for download...
  2. pmc Signatures of mutation and selection in the cancer genome
    Graham R Bignell
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 463:893-8. 2010
    ..The extensive copy number, genotyping, sequence and expression data available for this large series of publicly available cancer cell lines renders them informative reagents for future studies of cancer biology and drug discovery...
  3. pmc Statistical analysis of pathogenicity of somatic mutations in cancer
    Chris Greenman
    Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    Genetics 173:2187-98. 2006
    ..Significant selection pressure upon truncating mutations was established. Furthermore, an estimated minimum of 29.8 mutations were pathogenic...
  4. pmc Massive genomic rearrangement acquired in a single catastrophic event during cancer development
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
    Cell 144:27-40. 2011
    ..We find that one, or indeed more than one, cancer-causing lesion can emerge out of the genomic crisis. This phenomenon has important implications for the origins of genomic remodeling and temporal emergence of cancer...
  5. pmc GLO1-A novel amplified gene in human cancer
    Thomas Santarius
    Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK
    Genes Chromosomes Cancer 49:711-25. 2010
    ..Collectively the results indicate that GLO1 is at least one of the targets of gene amplification on 6p21.2 and may represent a useful target for therapy in cancers with GLO1 amplification...
  6. pmc A comprehensive catalogue of somatic mutations from a human cancer genome
    Erin D Pleasance
    Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 463:191-6. 2010
    ..The results illustrate the power of a cancer genome sequence to reveal traces of the DNA damage, repair, mutation and selection processes that were operative years before the cancer became symptomatic...
  7. pmc Complex landscapes of somatic rearrangement in human breast cancer genomes
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 462:1005-10. 2009
    ..The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development...
  8. pmc The relative timing of mutations in a breast cancer genome
    Scott Newman
    Hutchison MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    PLoS ONE 8:e64991. 2013
    ..Strikingly, the great majority of inactivating mutations and in-frame gene fusions happened earlier. The non-random timing of some of the mutations may be evidence that they were selected...
  9. pmc Estimation of rearrangement phylogeny for cancer genomes
    Chris D Greenman
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom
    Genome Res 22:346-61. 2012
    ..For cancer genes mutated in rearranged regions, this information can provide a chronological examination of the selective events that have taken place...
  10. pmc Systematic identification of genomic markers of drug sensitivity in cancer cells
    Mathew J Garnett
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 483:570-5. 2012
    ..By linking drug activity to the functional complexity of cancer genomes, systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies...